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Mitogen-activated protein kinases (MAPKs), which are found in all eukaryotes, are signal transducing enzymes playing a central
role in diverse biological processes, such as cell proliferation, sexual diﬀerentiation, and apoptosis. The MAPK signaling pathway
plays a key role in the regulation of gene expression through the phosphorylation of transcription factors. Recent studies have
identiﬁed severalRNA-binding proteins (RBPs)as regulators of MAPK signalingbecause these RBPs bind to the mRNAs encoding
thecomponentsoftheMAPKpathwayandregulatethestabilityoftheirtranscripts.Moreover, RBPsalsoserveastargetsofMAPKs
becauseMAPKphosphorylateandregulate theabilityofRBPstobindandstabilizetarget mRNAs,thuscontrollingvariouscellular
functions. In this review, we present evidence for the signiﬁcanceof the MAPK signalingin the regulation of RBPs and their target
mRNAs, which provides additional information about the regulatory mechanism underlying gene expression. We further present
evidencefortheclinicalimportanceoftheposttranscriptionalregulation ofmRNAstabilityanditsimplicationsfordrugdiscovery.
1.Introduction
Cells need to respond to a variety of signals including extra-
cellular stimuli, environmental stresses, and developmental
signals as well as intrinsic information, to properly regulate
gene expression and thereby execute biological functions.
Given the multiplicity and complexity of the regulation
of gene expression, failure to coordinate these regulatory
mechanisms can contribute to the onset and progression of
diseases such as cancer. Gene transcription and its regulatory
mechanisms, together with recent genome-wide approaches
forgenetranscription analysis, haveattractedthemostatten-
tion with regard to gene regulation. However, it has become
clear that additional stages in the gene expression cascade,
including posttranscriptional events such as the control of
mRNA degradation, stability, location, and translation, are
equally crucial and require sophisticated regulation by var-
ious intracellular signaling pathways [1]. RNA-binding pro-
teinshavebeenshown tocontrol theexpression ofnumerous
proteinsbybindingtotherespectivemRNAspeciesencoding
proto-oncogenes, growth factors, cytokines, transcription
factors, and other proteins in various cell types [2]. In
particular, the phosphoregulation of RNA-binding proteins
by MAPKs and/or kinases downstream of MAPKs, which
can control the degradation or translation of target mRNAs,
has attracted increasing attention. One of the most well-
studied model systems for the study of MAPK regulation
is the ﬁssion yeast Schizosaccharomyces pombe (S. pombe).
S. pombe, with its powerful genetics, is an excellent model
system forthestudyofthemechanisms ofsignaling pathways
in higher eukaryotes. In S. pombe, homologs of many
signaling molecules involved in tumorigenesis, such as Ras,
R h o ,P r o t e i nk i n a s eC ,a n dM A P K ,a sw e l la sd r u gt a r g e t s ,
including TOR (target of Rapamycin) and the phosphatase
calcineurin (target of the immunosuppressant drug FK506),
are highly conserved. Spc1/Sty1/Phh1 and Pmk1 in S. pombe
are homologs of mammalian p38 and ERK, respectively.
The purpose of this review is to highlight the signiﬁcance
of several data using the ﬁssion yeast model system as well
as other studies in higher eukaryotes that uncovered the2 Journal of Signal Transduction
cross-talk mechanism between MAPKs and RNA-binding
proteins (RBPs) in the regulation of posttranscriptional gene
expression, biological phenomena, and signal transduction
[3].
2.RNA-BindingProteinsasRegulatorsof
MAPKSignaling
Sugiura et al. developed a genetic approach to identify reg-
ulators of MAPK signaling on the basis of the antagonistic
relationship between calcineurin phosphatase and MAPK
Pmk1 in the regulation of Cl− homeostasis in ﬁssion yeast
(Figure 1)[4].By utilizingthisgeneticinteraction,Sugiuraet
al. identiﬁed several negative regulators of MAPK signaling,
including pmp1+, pek1+,a n drnc1+ (Figure 1). Pmk1 MAPK
isahomologueofERK/MAPKinmammalsandregulatescell
morphology, cytokinesis, ion sensitivity, and cell integrity in
ﬁssion yeast [5]. The ﬁrst gene identiﬁed encodes a dual-
speciﬁcity MAPK phosphatase Pmp1 that dephosphorylates
Pmk1 MAPK, thereby inhibiting Pmk1 signaling (Figure 1)
[4]. The second gene identiﬁed was pek1+,e n c o d i n ga n
MAPK kinase (MAPKK), which phosphorylates and acti-
vates Pmk1 in its phosphorylated form, thus acting as an
upstream MAPKK for Pmk1 (Figure 1)[ 6]. Surprisingly,
Pek1 in its unphosphorylated state binds phosphorylated
Pmk1, thereby inhibiting Pmk1 MAPK signaling. Hence,
Pek1 acts as a phosphorylation-dependent molecular switch.
The third identiﬁed gene encodes a novel KH-type RBP
(Figure 1), which shares signiﬁcant amino acid similarity
with human Nova-2, human FMR-1, and Caenorhabditis
elegans GLD-1. The third gene was designated as rnc1+
(RNA-binding protein that suppresses calcineurin deletion
1) because overexpression of the rnc1+gene suppressed Cl−
hypersensitivity of calcineurin-knockout cells (Figure 1).
2.1. MAPK Phosphatase mRNA as a Target of RNA-Binding
Proteins. Rnc1turnedouttobeanegative regulatorofPmk1
MAPK since Pmk1 MAPK was heavily phosphorylated in
Rnc1-knockout cells but was barely phosphorylated in cells
overproducing Rnc1. Based on the hypothesis that Rnc1
aﬀects the metabolism of speciﬁc cellular mRNAs involved
in the regulation of the Pmk1 signaling, the eﬀects of Rnc1
on the mRNA stability of the MAPK phosphatase Pmp1
were examined, because Pmp1 was identiﬁed in the same
genetic screen. The hypothesis is correct since Rnc1 binds
and stabilizes an otherwise unstable Pmp1 mRNA, thus
providing a novel functional link between MAPK signaling
and an RBP through the mRNA stabilization of MAPK
phosphatase (Figure 2)[ 7] .T h e s eﬁ n d i n g sa r ep a r t i c u l a r l y
important since Rnc1 directly aﬀects the expression of
MAPK phosphatase, thereby controlling the strength and
duration of MAPK signaling pathway.
Pmp1 ishighly similar to members ofthedual-speciﬁcity
MAPK phosphatase MKP-1 (MAPK phosphatase or DUSP1;
dual-speciﬁcity phosphatase1), which plays a critical role in
the negative regulation of MAPK signaling by dephosphory-
lating and inactivating ERK MAPK, JNK, and p38 [8–12].
Notably, Rnc1 recognizes and binds to the UCAU repeats
in the 3 -UTR (untranslated region) of the Pmp1 mRNA
(Figure 2)[ 7]. Mutations in the UCAU sequences greatly
destabilize Pmp1 mRNA owing to the lack of binding of
Rnc1 to Pmp1 mRNA [7]. Interestingly, the Nova-1 KH-
type RNA-binding protein, which has been implicated in
the pathogenesis of paraneoplastic opsoclonus-myoclonus
ataxia (POMA), a disorder associated with breast cancer and
motor dysfunction, binds to an element containing repeats
of the tetranucleotide UCAU [8]. It would be intriguing
to speculate that the mRNA stability of human MAPK
phosphatase might also be regulated by an RNA-binding
protein with or without KH-motifs.
Cell exposure to cytokines, growth factors, cell stresses,
or activated oncogenes leads to the activation of MAPK
and to the upregulation of mRNAs encoding a subset of
MAPK phosphatase genes [9–18]. This induction of MAPK
phosphatase expression has been extensively documented,
and it is considered to involve transcriptional induction by
various transcription factors, such as CREB and AP-1, via
both MAPK-dependent and MAPK-independent pathways
[19]. However, as shown in the study of Pmp1 in ﬁssion
yeast, MAPK phosphatase gene expression is regulated not
only by its transcription rate but also by its rate of mRNA
degradation in higher eukaryotes. Wong et al. reported that
heat shock increases MKP-1 gene expression at both the
transcriptional and posttranscriptional levels and the latter
involvesincreased mRNAstability of MKP-1 [20]. Moreover,
IthasbeenshownthatDUSP1/MKP-1mRNAisstabilizedby
oxidativestress-induced bindingofRBPsHuRand NF90[21,
22]. In addition, HuR promotes MKP-1 mRNA recruitment
to translation machinery and its translation eﬃciency.
Recently, Lin et al., Emmons et al., and Bros et al. sug-
gestedtheimportanceofTTP, azincﬁnger-AU-rich elements
(AREs) RBP, in the regulation of MKP-1 mRNA [23–25].
TTP has been shown to bind to AREs located in the 3 -
UTR of unstable mRNAs and to direct its target mRNAs
for degradation. By utilizing RIP-Chip analysis in human
dendritic cells, Emmons et al. identiﬁed 393 messages as
putative TTP targets, 33 of which contained AREs, including
dual speciﬁcity phosphatase1 (DUSP1/MKP1) mRNA. They
further conﬁrmed that the wild-type TTP signiﬁcantly
inhibits DUSP1/MKP1 expression by utilizing luciferase-
DUSP 3 -UTR reporter, which contains repeats of the
AUUUAsequences. Bros et al. revealed the role of TTP in the
degradationof MKP-1mRNA.Theyshowed elevatedexpres-
sion of TTP target mRNAs, including MKP-1, in TTP−/−
dendritic cells. Lin et al. also showed that biotinylated MKP-
1 AREs could bring down HuR and TTP in preadipocytes.
Therefore, MKP1mRNAis atarget ofseveralRBPsincluding
HuR and TTP, and these RBPs are involved in the mod-
ulation of MKP-levels and MAPK activity through mRNA
(de)stabilization of MAPK phosphatase, thus indicating that
MKP-1 expression is tightly regulated transcriptionally and
posttranscriptionally in many organisms, which ensures a
rigid feedback control of MAPK signaling.
2.2. Feedback Regulation of MAPK Signaling by an RNA-
Binding Protein. Interestingly, Rnc1proteininﬁssion yeast is
regulated by MAPK phosphorylation. There are six putativeJournal of Signal Transduction 3
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Figure 1: Molecular genetic approach to identify regulators of MAPK signaling using ﬁssion yeast model system. Upper panel: Calcineurin
phosphataseand Pmk1 MAPK pathway play antagonistic roles in Cl− homeostasisof ﬁssion yeast. Molecular genetic approach utilizing this
genetic interaction identiﬁed regulators of Pmk1 MAPK. Lower panel: Calcineurin deletion cells (CN KO) failed to grow in the presence
of 0.15M MgCl2. Overexpression of multicopy suppressor genes, including pmp1+ (MAPK phosphatase), pek1+ (MAPK kinase), and rnc1+
(KH-type RNA-binding protein) suppressed the Cl− sensitivity of the calcineurin deletion cells.
MAPK-phosphorylation sitesi nR n c 1p r o t e i na n dP m k 1
MAPK directly phosphorylates Rnc1 at T50 in vivo and in
vitro [7]. Notably, this phosphorylation by MAPK regulates
the RNA-binding activity of Rnc1, that is, the unphoshory-
latable T50A mutant Rnc1 failed to bind Pmp1 mRNA
while the phospho-mimic T50E mutation enhanced the
RNA-binding activity of Rnc1 [7]. Therefore, when Pmk1
signalingisactivated,Pmk1MAPKphosphorylatesRnc1and
the phosphorylated Rnc1 protein more potently binds and
stabilizes Pmp1 mRNA, resulting in upregulation of Pmp1
MAPK phosphatase, followed by the inactivation of Pmk1
signaling (Figure 2)[ 7]. Thus, the identiﬁcation of Rnc1 as
a target of the MAPK signaling cascade has revealed a novel
feedback mechanism for the posttranscriptional regulation
of MAPK phosphatase gene expression [7].
Similar negative-feedback mechanisms of the MAPK
signaling pathway through posttranscriptional mRNA sta-
bilization of MAPK phosphatase have been reported in
other organisms. As described above, Casals-Casas et al.
reported posttranscriptional mRNA stabilization of MKP-1
in macrophages and showed that this stabilization mecha-
nism was partly dependent on p38 MAPK [19]. Recently,
Bermudez et al. described the posttranscriptional regulation
ofDUSP6/MKP-3phosphatase byMERK/ERKsignaling and
hypoxia [26]. They showed that the MEK/ERK pathway
stabilizes dusp6 mRNA levels via its 3 -UTR. Moreover,
hypoxia,ahallmark oftumorgrowth,increasesdusp6 mRNA
stability in a MEK activity-dependent manner. Interestingly,
2 RNA-binding proteins, TTP, and PUM2, a homolog of
Drosophila pumilio protein, destabilize dup6 mRNA via its
3 -UTR. Therefore, although there is a diversity of the
MAPK pathways concerned between S. pombe and higher
eukaryotes, these studies suggest a conserved mechanism of
feedback-regulation mechanism of MAPK signaling through
the mRNA stabilization of MAPK phosphatase. Thus, it is
intriguing to speculate that some RBPs responsible for the
mRNA stability of the MAPK phosphatase gene(s) might
be regulated by p38 or ERK MAPK in higher eukaryotes.
Attractive candidates for such RBPs may include TTP, since
the well-known link between MK2 and TTP provides a
plausible explanation for posttranscriptional regulation of
MKP-1 by the p38 MAPK pathway.
3.RNA-Binding ProteinsasTargetsof
MAPK Regulation
The MAPK pathway is known to play an important role
in regulating gene expression, and this regulation has been
primarily attributed to the activation of transcription factors
via MAPK-dependent phosphorylation. However, since the
time p38 MAPK was found to play a major role in the
regulation of mRNA stability [27], accumulating evidence
suggests that the stability of mRNAs can be controlled
by RBPs under the regulation of various MAPK signaling
pathways in diﬀerent cellular systems [28–31]. These include
tristetraprolin (TTP) [32–34], nucleolin [35], hnRNP-K [36,
37], hnRNPA0 [38], HuD [39], and the poly(A)-binding
protein PABP1 [40], as well as Rnc1, Nrd1, and Csx1 in
ﬁssion yeast [7, 41, 42].
Since the activation of p38 MAPK and its downstream
MAPK-activated protein kinase-2 (MAPKAPK-2 or MK2)
signaling pathway leads to the stabilization of AU-rich
elements (AREs)-containing transcripts including various
inﬂammation genes, ARE-binding proteins are likely targets
for the p38 MAPK/MK2 pathway [43]. One of the well-
characterized RBPs is TTP, which acts as a substrate of p38
MAPK/MK2. TTP binds to the ARE motifs in the 3 -UTR of4 Journal of Signal Transduction
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Figure 2: Negative feedback regulation of MAPK signaling medi-
ated by an RNA-binding protein Rnc1. Rnc1 binds to the UCAU
repeats located in the 3 -UTR of the Pmp1 mRNA. The activated
Pmk1 phosphorylates Rnc1, leading to the enhanced activity of
Rnc1, thereby binding to and stabilizing an otherwise unstable
Pmp1 mRNA. Upregulated Pmp1 dephosphorylates and inactivates
Pmk1, thus creating a negative-feedback loop that regulates the
MAPK signalling.
several cytokine mRNAs including TNFα mRNA and targets
them for degradation, thereby suppressing inﬂammation
[33]. TTP−/− mice developed severe inﬂammatory symp-
toms, including cachexia, spontaneous arthritis, dermatitis,
and neutrophilia, mainly because of the overproduction of
TNFα resulting from the increased stability of the TNF
mRNA and subsequent higher rates of secretion of the
cytokine [44]. Notably, macrophages derived from TTP−/−
MK2−/− double knockout mice showed highly increased
amounts of TNF almost identic a lt ot h o s ei nT T P - d e ﬁ c i e n t
mice, whereas in MK2-null mice, the TNF level was dra-
matically reduced in MK2-deﬁcient animals compared to
the wild type [45]. This genetic evidence strongly suggests
that TTP is the main downstream element of MK2 in
the posttranscriptional regulation of TNF in vivo.M K 2
directly phosphorylates TTP at 2 serine residues (Ser52 and
Ser178 in mouse TTP) in vitro and in vivo (Figure 3)[ 46].
Furthermore, TTP can be directly phosphorylated by p38
(Figure 3)[ 32].
Notably, phosphorylation by MK2 inhibits TTP activity.
Several studies have described the molecular mechanisms
underlyingthisregulation,althoughthissubjectiscontrover-
sial. The phosphorylation of TTP by MK2 facilitates the dis-
sociation of TTP from the ARE motif, thereby allowing the
biosynthesis of TNFα [45]. Previous studies have also shown
that MK2 is required for the maintenance of normal TTP
levels and phosphorylation by MK2 leads to stabilization
of TTP and inhibition of its mRNA destabilization activity.
Notably, the phosphorylation of TTP at 2 serine residues
(Ser52andSer178)allowsbindingof14-3-3adaptorproteins
(Figure 3)[ 47, 48]. Furthermore, Stoecklin et al. showed
that MK2-dependent phosphorylation of TTP releases it
from stress granules and inhibits degradation of mRNAs
containing AREs (Figure 3)[ 48]. Interestingly, recent studies
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Figure 3: Control of ARE-containing mRNA degradation by TTP.
Unphosphorylated TTP binds to the ARE and promotes degra-
dation of the mRNAs. MK2 phosphorylates TTP at two serine
residues, andthisphosphorylationallowsbindingof14-3-3adaptor
proteins and stabilization of the ARE-containing target mRNAs,
such as TNFα. TTP canalso be phosphorylated by p38. Phopshory-
lation also excludes TTP from stress granules.
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Figure4:TheregulationofmRNAinMAPKsignaling.MAPkinase
signaling pathways regulate both transcriptional and posttran-
scriptional gene expression in various organisms. MAPK-signaling
mediated phosphorylation regulates transcription factors and/or
RNA-binding proteins, which resulted in mRNA regulation. Precise
regulatory mechanism(s) of these proteins by MAPK signaling are
not fully understood.
by Marchese et al. and Clement et al. described a molecular
mechanism for the regulation of TTP function by MK2,
involving the inhibition of recruitment of a deadenylase
complex [49, 50]. In addition to TTP, MK2 also phospho-
rylates poly(A)-binding protein [40]a n dh n R N P A 0[ 51],
thereby regulating their mRNA-binding capacity. Moreover,
p38 MAPK phosphorylates the KH-type splicing regulatory
protein (KSRP) and inhibits its binding and destabilization
of mRNAs coding for proteins involved in the diﬀerentiation
of myoblasts into myotubes, thus indicating that p38 regu-
lates mRNA turnover by targeting KSRP [52].
Interestingly, the budding yeast p38 homolog Hog1
was shown to be essential for stabilization of these ARE-
containing mRNAs [53], thus indicating that MAPKs also
regulate mRNA stability in lower eukaryotes. In ﬁssion yeast,
there is an interesting association between p38 and Csx1,
an RBP crucial for survival following oxidative stress inJournal of Signal Transduction 5
S. pombe [42]. Csx1 is an RRM-type RBP with signiﬁcant
amino acid similarity to TIA1 in higher eukaryotes. Csx1 is
phosphorylated upon oxidative stress in a Sty1-dependent
manner. Csx1 associates with and stabilizes atf1+ mRNA,
which encodes a member of the ATF/CRE-binding protein
family of transcription factors, including ATF2, in higher
eukaryotes [42]. Moreover, Csx1 controls expression of the
majority of the genes regulated by Spc1 p38 and Atf1 in
response to oxidative stress. Notably, HuR RBP in higher
eukaryotesstabilizes ATF-2 mRNAby binding to the 3 -UTR
of ATF-2 mRNA in response to polyamine concentrations
[54]. Consistently, HuR overexpression and depletion mod-
ulates ATF-2 mRNA abundance and resistance to apoptosis.
These studies reveal a highly conserved mechanism of
controlling MAPK-regulated transcription factors as well
as several physiological responses, including oxidative stress
and apoptosis through RBP.
4.Other Instancesof MAPK-Mediated
Phosphoregulationof RBPs:Cell Cycle
ControlMediated by Modulation
ofmRNA Stability
Recent paper by Satoh et al. revealed an interesting link
between RBP and cell cycle control mediated by modulating
myosin mRNA stability [41]. They identiﬁed Nrd1, a highly
conserved RNA-recognition motif (RRM)-type RBP, as a
regulator of Cdc4, an essential myosin light chain, a key
regulator of cytokinesis in ﬁssion yeast [55, 56]. Nrd1 binds
to Cdc4 mRNA in vivo and in vitro, thereby stabilizing
Cdc4mRNAand regulating cytokinesisin ﬁssion yeast. Nrd1
shows signiﬁcant sequence similarity with TIA-1 and the
TIA-1-related (TIAR) proteins in higher eukaryotes [57, 58].
It has been reported that both TIA-1 and TIAR bind to RNA,
with the preferred binding sequence being U-rich including
the UCUU motifs present in the mRNAs [59, 60]. Notably,
the mutation in the two UCUU sequences (cdc4M1M2)
within the Cdc4 ORF abrogated the binding between Nrd1
and Cdc4 mRNA, and the cdc4M1M2 mutant cells exhibited
cell separation defects, suggesting that the loss of Nrd1
binding aﬀects cytokinesis.
Interestingly, Nrd1 is also phosphorylated by Pmk1
MAPK at two threonine residues (T40 and T126) and this
phosphorylation negatively regulates Nrd1 activity to bind
and stabilize Cdc4 mRNA and cytokinesis. Nrd1DD,t h e
phosphorylation mimic version of Nrd1, only weakly binds
to Cdc4 mRNA, while Nrd1AA, the unphosphorylatable
version of Nrd1, in which T40 and T126 are substituted by
alanine residues, strongly binds to Cdc4 mRNA [41]. The
deletion of Pmk1 MAPK, similar to Nrd1 overexpression,
stabilizes Cdc4 mRNA, thus providing the ﬁrst example of
MAPK-mediated cell cycle control through mRNA stabiliza-
tion of myosin via RBP.
There are also interesting examples of cell-cycle control
by modulation of mRNA stability in higher eukaryotes,
especially with regard to DNA damage checkpoints [61].
Reinhardt et al. reported the involvement of MK2 activity
in the regulation of Gadd45α mRNA stability [38]a n d
showed that the p38/MK2-dependent phosphorylation of
3k e yt a r g e t si n v o l v e di nR N Aregulation-hnRNP0, TIAR,
and PARN-stabilizes an otherwise unstable Gadd45α mRNA
through its 3 -UTR, resulting in increased Gadd45α protein
levels. Gadd45α itself is then required to maintain MK2
activity, which is critical for prolonged Cdc25 inhibition and
maintenance of a G2 arrest [38]. Thus, the positive feedback
loop involving p38/MK2/Gadd45α is essential to allow cells
to recover from DNA damage, before committing to the
next mitotic cell division. These reports on RBP-mediated
cell-cycle control through mRNA stability provide further
evidencefor the phosphoregulation ofRBPs through MAPK,
thereby revealing an additional level of cell cycle regulation.
5.ClinicalImportance ofthe
PosttranscriptionalRegulation
of mRNAStabilityand ItsImplications
forDrug Discovery
Considerable number of genes that code for AU-rich
mRNAs, including cytokines, chemokines, growth factors,
RBPs, and transcription factors, are commonly involved
in both chronic inﬂammation and cancer [62]. Therefore,
stabilization of the ARE-mRNAs via RBP can cause pro-
longed responses that subsequently may lead to chronic
inﬂammatory diseases, such as rheumatoid arthritis and
cancer. Indeed, neutralizing antibodies to TNFα,o n eo f
the most important proinﬂammatory cytokine containing
AREs, prevent arthritis in transgenic mice expressing ARE-
lacking stable TNFα transcripts, which produce pathological
overexpression of TNFα [63, 64]. Thus, abrogation of
posttranscriptional pathways that mediate the expression of
these proinﬂammatory genes may serve as a clinical target of
inﬂammation. Furthermore, since the expression of MAPK
phosphatase is closely linked to inﬂammation as well as
malignancies of various cancer cells, targeting the mRNA
expression of MKPs could represent a promising thera-
peutic target and elucidation of these mechanisms would
be highly important for understanding the mechanism of
cancer and inﬂammation. Since abnormal activation of the
Ras/Raf/MAPK pathway can lead to cancer and since the
p38/MK2pathway plays a crucialrole in inﬂammation, these
MAPKs, together with the RBPs that regulate MAPKs, are
attractive targets for new therapies for both cancer and/or
inﬂammatory diseases such asCrohn’s diseaseorrheumatoid
arthritis. A large body of evidence from preclinical studies
indicate a crucial role of p38 MAPK signaling in inﬂam-
mation, and drugs that target p38 or MK2 and those that
inhibit the development of inﬂammatory arthritis in mouse
models are being investigated for the treatment of patients
with rheumatoid arthritis and inﬂammatory bowel disease
[65–67].
6.ConcludingRemarks
We have presented several examples of functional relation-
ships and cross talk regulatory mechanisms between RBPs
and MAPK signaling in ﬁssion yeast model system and6 Journal of Signal Transduction
have drawn some parallels with animal cells. A recent paper
by Belle et al. on the global investigation of protein half-
lives in budding yeast indicates that the protein products
of genes that are coregulated on the transcriptional level
also tend to be coregulated on the level of protein turnover
[68]. Similarly, it would be intriguing to see the correlation
between transcriptional and posttranscriptional regulation,
since ERK MAPKs and the p38/MK2 axis regulate both
the transcriptional and posttranscriptional gene expression
of various immediate early genes involved in inﬂammation
and stress responses [69]. Further studies are required to
clarify the complex interplay between these transcriptional
and posttranscriptional events during inﬂammation and
cancer, and its regulation by RBPs and various signaling
pathways including MAPKs pathways and others (Figure 4).
Moreover, it would be important to elucidate the basis for
t h ec o o p e r a t i v ea c t i o no fp 3 8M A P Ka n dE R Kp a t h w a y s
for optimal ARE-mRNA stabilization [70]. To clarify these
mechanisms, the use of a simple eukaryotic model organism
such as ﬁssion yeast could contribute to the ﬁeld, since many
RBPs and signaling pathways, including MAPKs and the
major pathways of mRNA degradation and transcription,
are highly conserved. Altogether, these data highlight an
emerging role for RBPs as regulators of MAPK signaling and
future targets for drug discovery.
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